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Abstract 
 
 Problem: 5% human albumin is used very frequently in the hospital setting with 
 hypotensive post-surgical patients. There are associated risks with the use of    
human  albumin and it has been shown that normal saline is at least as effective in 
treating extreme hypotension in this patient population. 
Significance: Associated risks that are present with the use of human albumin 
may be equal to those of the risks of whole blood transfusions. In addition weight 
gain and fluid retention are complications associated with the use of human 
albumin versus the use of normal saline. Furthermore, human albumin costs  
$40.59 more than normal saline solution. 
 Methods:   Literature review and the IOWA Model. 
Results:  Patients who are not at risk for post-perfusion syndrome, pulmonary 
hypertension, on strict intake and output regulation, or increased vascular 
permeability and are experiencing hypotension secondary to hypovolemia post-
operatively would benefit from normal saline as a first line therapy. 
Key words: hypotension, fluid resuscitation, fluid loss, hypovolemia, cost,  
 
safety, post-operative, colloid, crystalloid, human 
 
albumin, 5% albumin, normal saline, saline 
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Chapter One: Introduction 
Introduction 
Current practices of fluid resuscitation for the treatment of hypotension secondary 
to hypovolemia in the adult post-operative patient are inconsistent and may place the 
patient at risk with the chosen treatment.  Despite previous evidence-based administration 
guideline recommendations, it was found that human albumin was inappropriately used 
for 57.8% of adult patients (Boldt, 2010). 
Currently, hospitals lack recommendations to assist in the selection of the 
appropriate treatment. The chosen treatment is dependent on the surgeon’s preference and 
is not necessarily evidenced-based (Roberts, et al., 2011). Human albumin solutions and 
saline solutions are used frequently in emergent and post-surgical patients to stabilize 
extreme hypotension and low blood pressure due to fluid loss. Human albumin solutions 
are more expensive than other comparative colloids and crystalloids, but the major 
consideration is the safety profile of the human albumin. Normal saline has been found to 
be at least as effective as 5% human albumin solution at treating hypotension and in turn 
it is a sustainable alternative to human albumin (Roberts, et al., 2011).   
Through successful conclusion of this project I was able to promote the most 
efficacious, safe, and cost-effective evidence-based recommendation possible to the 
patient population.  By analyzing the current research on the effect of human albumin vs. 
normal saline in the outcome of post-surgical patients who experience extreme 
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Chapter Two: Model 
Iowa Model 
 The Iowa Model of Evidence-Based Practice to Promote Quality Care is a useful 
model for the nurses to follow in order to know how to begin, develop, and assess 
evidence-based practice (Burns & Grove, 2009). This model can be used to help nurses 
make daily decisions in the care of their patients. The Iowa Model provides a framework 
allowing for all members of the healthcare team to be included in the quality change. For 
this reason, I chose this model. It allows the change to be a team effort and increases the 
likelihood of a successful implementation a successful implementation (Burns & Grove, 
2009).  
There are seven steps in the Iowa model (Doody, C.M, & Doody, O.,2001). The 
first step is to select a topic. The topic should be a trigger for needed change such as a 
clinical problem. Changes are necessary to keep nursing practices current. The use of the 
best evidence to provide effective and cost-appropriate treatment is the goal of the 
changing current practices. The topic should have a large amount of data and evidence in 
the area of need. Forming a team is the second step in the Iowa model. The team should 
consist of at least one person under the guidance of a committee. Team responsibilities 
include development, implementation, and evaluation of the EBP. (Doody, et al.,2001).  
 The third step is evidence retrieval.  This is simply searching for the evidence 
necessary to address the problem of focus and then to use the evidence to recommend 
change the current practice.  There must be sufficient data to support the propose change. 
3
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the area of need. Forming a team is the second step in the Iowa model. The team should 
consist of at least one person under the guidance of a committee. Team responsibilities 
include development, implementation, and evaluation of the EBP. (Doody, et al.,2001).  
 The third step is evidence retrieval.  This is simply searching for the evidence 
necessary to address the problem of focus and then to use the evidence to recommend 
change the current practice.  There must be sufficient data to support the propose change. 
A paucity in the literature would indicate the topic is not appropriate for an evidence-
based project, but for a research thesis. Grading the evidence is the fourth step and allows 
the person developing the project to evaluate the effectiveness, appropriateness, and the 
feasibility of an appropriate outcome (Doody, et al.,2001).  
The fifth step is to develop the evidence-based recommendation standard: “This 
sets the standard of practice guidelines, assessments, actions, and treatment as required” 
(Doody, et al.,2001).  The recommendation that I developed included both the pros and 
cons found in the literature. The standard should be supported by the pros, but caregivers 
need to be aware of the limitations of the treatment to provide efficient care. 
 The sixth step is to implement the recommendation. This step requires interaction 
between all levels of care. Management and direct care employees need to be trained with 
the new practice and the new recommendation by a member of the committee.  If workers 
understand the benefits of this change, they will be more likely to comply with the new 
recommendation (Doody, et al.,2001). The seventh and final step is to evaluate the 
project’s level of change and value. Ultimately this step is used to see how well the 
project was implemented and to achieve a solution to the problem trigger (Burns & 
Grove, 2009). 
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Chapter Three: Framework 
Synthesis of Data Retrieval 
To complete the review of literature, I began on the Cedarville University 
Centennial Library’s website. I used the “multiple databases” tab to select the following 
databases: CINAHL Plus with Full Text, Cochrane Central Register of Controlled Trials, 
and Cochrane Database of Systematic Reviews. The advanced search tab allowed me to 
narrow down my findings. I did not select the option for “results with full text” as this 
may have excluded articles that could be requested from other libraries.  
I also selected the “peer reviewed” and “evidenced-based” article options, and the 
initial timeline was set to gather articles from within the last five years. The timeline 
eventually expanded to 10 years, with the exception of one article. This article was 
repeatedly listed as a reference in current articles, indicating its validity for current 
research. Once I had reviewed the articles, I checked their references for additional 
articles and searched for those which were relevant.   
Search Terminologies 
 I used the following terms to narrow the evidence findings: “hypotension”, “low 
blood pressure”, “post-surgical”, “fluid loss”, “hypovolemia”, “cost”, “treatment”, 
“therapy”, “illness”, “guidelines” and “adverse effects” in combination with either 
“human albumin” or “normal saline”. I also used the following as substitute terms for 
normal saline: “saline”, “0.9% saline”, and “crystalloid”.  For “5% human albumin”, I 
5
substituted the terms “human albumin”, “albumin”, “5% albumin” and “colloid”. Not 
every search needed to include human albumin and normal saline together. I was able to 
gather research data that was related to one or the other and gain insightful data about that 
solution. 
Inclusion & Exclusion Data 
 The inclusion data is very broad. The patients must be hospitalized, living, adult 
humans, of any race or any gender. The unit in which the recommendation was presented 
was an adult cardio-thoracic care unit. The patient population consisted of postoperative 
adults and included a high level of patients for whom strict intake and output regulation 
was monitored. Currently, 5% human albumin is given for hypotension secondary to 
hypovolemia for most patients. While this recommendation is based on the surgeon’s 
preference, patients recovering from a coronary artery bypass graft may have two bottles 
of 5% human albumin for a total of 500 ml per standing order to treat mean arterial 
pressures lesser than sixty mm Hg or for urine output less than thirty mL over one hour.  
Articles were considered from all countries, as inclusion of only articles from the United 
States would have considerably limited the search results. The articles needed to include 
the administration of 5% human albumin and/or normal saline to a patient. I considered 
articles that included either normal saline or 5% human albumin even if the title did not 
mention a hypotensive situation. As a result, I was able to review a broader base of 
literature. 
 I excluded articles unrelated to in-patient related fluid replacement therapy. I also 
excluded articles that were not published or updated in the last ten years, except for the 
article that was repeatedly referenced by current articles. If the article did not use adults 
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only, the research was excluded. I did not initially account for sample size, but I 
considered its impact during the evaluation of each article.  
 Ethical Considerations 
I did not implement research on human subjects, and I did not need approval from 
the Institutional Review Board (IRB). This final outcome of this evidenced-based 
research project was based upon completed research to date. I did not actively collect 
data with human participants. 
 Any negative effects regarding use of saline over human albumin or vice versa 
that led to a negative outcome would have been an ethical dilemma. If the outcome of the 
literature review had resulted in a possible negative outcome for the patient, I would not 
have recommended that specific replacement therapy. 
Specific Timeline 
 
 I needed to finish retrieving and grading evidence by March 14, 2013. I needed to 
develop an evidence-based recommendation or recommendation and present it to my unit 
Nurse Educator and stakeholder, Dawn Myers, by June 14, 2013. I met with one of the 
hospital’s main cardiothoracic surgeon’s, Dr. Pavlina, MD on August 2, 2013. I met with 
my Evidence Based Project Committee intermittently throughout this timeline. 
Evidence Based Project Committee 
 
 Amy Voris, DNP, CNS, AOCN, Rachel Parrill, PhD, APHN-BC, Dawn Myers, 
MSN, RN were on the committee of my evidenced- based project. They were a great 
reference to facilitate the growth of my project and, in the end, successfully implement 
my evidenced-based recommendation. In the subsequent chapter, I have outlined the 
results of the literature review.  
7
  
 
Chapter Four: Literature Review & Results 
Methodology 
For this review of literature, I accessed the following databases: Cedarville 
University CINAHL Plus with Full Text, Cochrane Central Register of Controlled Trials, 
and Cochrane Database of Systematic Reviews.  I used the following key words to 
research related study reports, articles, and research studies:” hypotension”, “fluid 
resuscitation”, “fluid loss”, “hypovolemia”, “cost”, “safety”, “post-operative”, “colloid”, 
“crystalloid”, “human albumin”, “5% albumin”, “normal saline”, and “saline”. The time 
frame of the literature search was about eight days, and twenty articles were found. Two 
articles were not accessible through inter-library loan, and five articles were excluded 
from the review. I have outlined inclusion and exclusion of articles in the next section.  
Inclusion & Exclusion Data 
Inclusion. Articles were required to have included patients that were post-
surgical. Fluid resuscitation was also required as a treatment for hypotension.  I preferred 
studies that used either normal saline or 5% human albumin, but I considered all 
crystalloids and colloids used for a more general outcome regarding the overall 
classification. I focused on trends in cost, efficacy, and safety within the classes.  
I also included studies that involved some but not all post-surgical patients were 
included. The outcome of the study, however, needs to reflect the difference in risk 
between post-surgical and non-post surgical patients in regard to fluid resuscitation. I 
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included studies that used human albumin and normal saline on non-surgical patients 
only if information regarding cost or safety (i.e., blood borne diseases) was included. 
Exclusion. I excluded one article that included fluid resuscitation of a dialysis 
patient with no presence of a recent surgery. I excluded four articles due to their focus on 
the neonatal population.  
Thirteen articles were reviewed, analyzed, and graded on their level of evidence 
based on the Levels of Evidence for Primary Research Question criteria (Rahman & 
Pukui, 2002). The grading criteria can be found in Appendix A. The results of the 
analysis are listed below and are specified by author, year published, title, design of the 
research, specific solutions compared, and the level of evidence. 
Review of Literature 
Fluid resuscitation is a common first-line treatment for hypotension related to 
hypovolemia and results in a “rapid increase of cardiac output and tissue oxygenation” 
(Trof, Sukul, Twusj, Girbes, & Groeneveld, 2010, p 697). Crystalloids and colloids are 
the two types of fluid available. The patient’s specific necessities are the determinant of 
which type of fluid is provided. 
Crystalloids are fluids that are given to maintain electrolyte and fluid equilibrium 
(Ignatavicius, D., & Workman, L, 2006).  Ringer’s lactate and normal saline are common 
crystalloids. Ringer’s lactate is a mixture of potassium, sodium, chloride, calcium, and 
lactate that is dissolved in water. This solution is isotonic and is appropriate to be used to 
expand volumes, and the added lactate is appropriate to buffer out acidosis. Normal 
saline is a mixture of 0.9% sodium chloride and water.  It is good for fluid replacement to 
increase the intravascular volume. Crystalloids are good options for fluid 
9
replacement/expansion when there is no loss of red blood cells (Ignatavicius, et al., 
2006).   
Colloids are fluids that contain protein and are given to reestablish osmotic 
pressure and expand the intravascular fluid volume (Ignatavicius, et al., 2006). Colloids 
include whole blood, packed red blood cells (PRBCs), plasma, plasma fractions, and 
synthetic plasma expenders. Human albumin is a plasma protein fraction. Plasma protein 
fractions and synthetic plasma expanders are given when hemoglobin and hematocrit are 
within normal ranges and creates the benefit of an increase in osmotic pressure 
(Ignatavicius, et al., 2006). A plasma protein fraction, such as human albumin 5%, is not 
able to improve the oxygen-carrying function as whole blood or PRBCs can 
(Ignatavicius, et al., 2006).   
Efficacy, safety, and cost are analyzed in the subsequent sections. The summary 
and limitations to the studies are successive to efficacy, safety, and cost with the literature 
reviewed referenced in Table 1 and Table 2 in the conclusion of this section. Table 1 
includes the literature reviewed that supports the use of Human Albumin in the adult 
post-operative patient who is experiencing hypotension secondary to hypovolemia. Table 
2 includes the literature reviewed that supports the use of Normal Saline in the adult post-
operative patient who is experiencing hypotension secondary to hypovolemia. 
Efficacy. Efficacy is defined as “the power to produce an effect” (Merriam-
Webster). The chosen treatment must have a positive effect for the patient and be at least 
as or more efficient than alternative therapies. The effect of human albumin or normal 
saline must create in increase of blood pressure in order to correct the hypotension 
secondary to hypovolemia.  
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The SAFE Study compared mortality rates of patients between those who 
received 4% human albumin versus normal saline. These authors reported that human 
albumin and normal saline resulted in similar outcomes at 28 days for ICU patients. 
(Finfer, S., Bellomo, R., Boyce, N., French, J., Myburgh, J., & Norton, R. (The SAFE 
Study Investigators), 2004). Although, these researchers used 4% albumin and not 5% 
albumin this is not a significant variation. These researchers further report that 1) Net 
intake of normal saline was not significantly greater than that of human albumin, 2) there 
was no difference between groups on packed red blood cell use, and 3) central venous 
pressures were higher in the human albumin group indicating a higher amount of 
intravascular fluid. (Finfer,et al, 2004). This data supports that normal saline may be as 
effective as human albumin for the treatment of hypotension secondary to hypovolemia. 
When monitoring the hemodynamic variables of the post-op patient, 5% human 
albumin has been found to have a greater volume expanding effect and a greater increase 
in the cardiac index when compared to normal saline up to a maximum infusion of 
1800ml (Verheij, J., Van Lingen, A., Beishuizen, A., Christiaans, H., De Jong, J., Girbes, 
A., Groeneveld, A., 2006). Central Venous Pressures were increased by both solutions, 
but normal saline was less effective than human albumin. (Verheij, et al., 2006). 
Kruer and Ensor (2012) discussed the importance of the colloid osmotic pressure 
(COP) and the length of time that the solution is retained in the intravascular system. The 
safety of the patient may be considered in the length of efficacy of the solution. The 
volume expanding properties of colloids remain effective for up to twenty fours hours 
while the maximum benefit of crystalloids is four hours (Kruer et al., 2012).  
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In post-operative patients, especially cardiac bypass patients, the risk for post-
perfusion syndrome (PPS) is high.  Post perfusion syndrome causes a shift in the 
intravascular fluid due to the inflammatory response prompted by the surgery (Kruer et 
al., 2012). The histological changes show engorgement of the pulmonary vascular bed, 
mircro-atelectasis and interstitial and alveolar hemorrhage. “Renal insufficiency, 
neurologic changes and hemorrhagic diathesis are additional indications of postperfusion 
syndrome” (Stoutenbeek, C., & Oudemans-van Straaten, H., 1990, p. 378). Use of a 
crystalloid would only exacerbate this syndrome and result in excessive fluid in the 
interstitial space.  Patients at risk for third spacing benefitted from human albumin as the 
need for blood transfusion was decreased (Diehl-Oplinger, L., & Kaminski, M. F. (2004). 
Colloids, such as 5% human albumin, helped to maintain the colloid oncotic pressure and 
decrease the chance of hypovolemia due to fluid shifting (Kruer et al., 2012).  
In contrast, findings from Devlin & Berletta (2005) were that crystalloids have 
been found to be more effective at volume expansion of intravascular and the interstitium 
and to have a more rapid equilibrium than when compared to colloids. These results 
argue that the use of a crystalloid results in a lower risk for pulmonary edema and 
improving overall organ function. Colloids help to sustain and return the volume and 
blood flow while normal saline and other crystalloids lower the concentration of the 
plasma. A lower COP results in a diminished length of time that the volume is retained in 
the intravascular system and is shifted into the interstitium (Trof, R., Sukul, S., Twisk, J., 
Girbes, A., & Groeneveld, A., 2010). This would theoretically result in more volumes of 
a crystalloid be given. However, the Saline versus Albumin Fluid Evaluation Study 
(SAFE) study mentioned above was only a ratio of infused human albumin vs. normal 
12
saline of 1:1.4. Mean arterial pressures responded similarly with the treatment of human 
albumin and saline. This led to inconclusive evidenced-based findings (Finfer, et 
al.,2004).    
In distinction to the findings of the SAFE study, crystalloid solutions are more 
likely to result in fluid overload because they are more quickly shifted into the 
interstitium. According to Verheij, et al. (2006) there are conflicting studies about the 
ratio of colloid to crystalloid needed.  Verheij et al (2006) illuminated that cardiac and 
vascular patients were not included in the SAFE study and that “the retention of albumin 
is greater than that of saline after cardiac surgery, as inferred from measurements of 
plasma and extravascular fluid volumes” (p. 1036). This highlights that the conclusions 
found in the SAFE study are not applicable to patients who have undergone cardiac or 
vascular surgeries as the research has not been completed to support them. 
Safety. Albumin is a nonsynthetic solution and has been found to increase risk for 
infections and allergic reaction (Kruer et al., 2012). Andrews (2011) outlined that human 
albumin carries“…cost implications as well as the potential for transmission of blood-
borne viral disease such as Creutzfeldt-Jakob Disease (CJD)” (p 136). Human albumin is 
a blood protein and carries the risk for immune hypersensitivity, including anaphylactic 
shock, viral disease transmission (HIV/AIDS, Hepatitis, etc.), prion disease transmission, 
and possible increased edema formation once it is present in the interstitium (Robert & 
Bratton, 2008; Fortin, Bassett, & Musini, 2010).  Robert & Bratton clarify that prion 
diseases and transmissible spongiform encephalopathy are always fatal (2008).  
In difference, many clinicians have thought that human albumin administration 
could reduce mortality in hypovolemic patients (Perel, P., & Roberts, I., 2012; Roberts, 
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Blackhall, Bunn, & Schierhout, 2011). Vincent, Navickis, & Wilkes (2004) argued that 
the use of human albumin reduced morbidity in critically ill patients. In another study, 
5% human albumin did reduce mortality among cardiac surgery patients when compared 
to crystalloid-only resuscitation (Kruer et al., 2012).  
The average infusion ratio for human albumin to normal saline was 1:1.4. Despite 
this ration, Perel (2012) stated that the risk of fluid overload of the patient was also no 
longer a risk when compared to normal saline (p 5). Perel (2012) affirmed that the use of 
human albumin over normal saline was not justifiable as human albumin does not 
increase survival rate, there are additional risks compared to normal saline, and there is a 
significant cost increase with human albumin. 
  Cost. In addition to safety and efficacy the expense of the solutions is a 
significant factor when considering the appropriate use of human albumin versus normal 
saline (Roberts et al., 2008; Talasaz, A., Jahangard-Rafsanjani, Z., Ziaie, S., Fahimi, F., 
2012). The national average cost of one 250ml vial of 5% human albumin is $41.00 (FFF 
Enterprises, 2011). The cost of one 250ml bag of 0.9% normal saline is $1.30 (PMI, 
2012). At this cost ratio, over 31 bags of 0.9% normal saline could be purchased and to 
provide patient care for the cost of one 250ml vial of 5% human albumin. Kettering 
Medical Center Network purchases the 250 ml 5% human albumin vials at $36.00 per 
vial and the 250 mL bags of normal saline for $25.06 per case of 36 bags (Michelini, 
2013). At this cost ratio, over 51 bags of 0.9% normal saline could be purchased for the 
cost of one 250ml vial of 5% human albumin. 
Talasaz et al (2012) concluded that albumin was a costly treatment that was being 
used improperly. The researchers who conducted the SAFE Study indicated that the 
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decision to use human albumin versus normal saline should take into consideration the 
providers reference, cost, safety, and the individual needs of the patient (Finfer et al. 
2004). This limits the ability to have a fixed recommendation. There must be a margin for 
critical thinking and the best evidence practice for the individual needs of the patient. 
Summary. To maximize the efficacy of the solutions used. Talasaz, et al (2012) 
attempted to correlate the American Society of Hospital Pharmacist (ASHP) 
recommendation with the relevance of human albumin usage. The study failed to 
correlate albumin use with decreasing mortality rates, time in the hospital, length of time 
needed on mechanical ventilation, or renal replacement therapies (Pettila & Ruokonen, 
2005; Finfer, et al., 2004) Intensive care settings include most of the appropriate 
situations for human albumin including but not limited to: hypervolemia, cardiac surgery, 
acute respiratory distress syndrome (ARDS), organ transplant, and cerebral ischemia 
patients (Talasaz, A., et al., 2012, 85-86).  
Limitations. The SAFE study, which is the basis of many current fluid 
resuscitation recommendations and research reviews was a very large study with 
approximately 7,000 patients, though it excluded cardiac and vascular patients (Verheij, 
et al., 2006). This excludes a wide span of the patient population that is administered 
human albumin on a daily basis. There are a significant number of studies on the efficacy 
and safety of human albumin versus normal saline but they have resulted in mixed 
conclusions and with mostly small sample sizes and incomplete patient populations 
(Devlin and Barletta, 2005). 
 Devlin, et al. was graded at a Level II of evidence and may result in a 
recommendation of fair support of evidence. The Safe study written by Finfer, et al and 
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the research completed by Verheij, et al. are graded as a Level I of evidence. While these 
are both strong pieces of research they would separately be graded as an A or as being a 
good recommendation that is supported. With conflicting or inconsistent research to 
argue their points a recommendation of B or fair support of a recommendation would be 
given. However, both articles are clear that the patient population and specific needs 
should be analyzed prior to treatment. There is not a gold standard to eliminate the need 
for individualization of care. Critical thinking and judgment should be used to develop 
the best plan possible. For generalization purposes and when not focusing on one specific 
patient population, normal saline can be used as the guideline recommendation as 
evidenced by the SAFE study (Finfer, et al, 2004). This would be applicable to an A or of 
good recommendation quality.  
Both Level I and Level II articles bear mixed conclusions. The SAFE study 
specifically outlined that if the patient does not fit generality to the study, i.e. cardiac or 
vascular complications, the treatment choice should rely on outlying factors: “According 
to the current state of knowledge, factors that may influence the choice of resuscitation 
fluid for a critically ill patient include the individual clinician’s preference, the 
tolerability of the treatment, its safety, and its cost” (Finfer, et al., 2004). This limits the 
standardization of the recommendation of use of human albumin versus normal saline. 
Evidenced Based Clinical Recommendations 
Patients who are experiencing hypotension secondary to hypovolemia post-
operatively, are not on strict intake and output regulation, and are not at risk for post-
perfusion syndrome, pulmonary hypertension, or increased vascular permeability would 
benefit from receiving normal saline as a first line therapy. 5% human albumin would 
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provide minimal benefit for these patients and risks associated with it would not be 
justified. If the normal saline has failed to correct the hypotension, human albumin may 
be used. This is a grade B recommendation. The levels of evidence presented are I and 
III. This recommendation includes multiple meta-analyses but does not consist of a 
randomized control trial or a non-randomized control trial. The strength of this 
recommendation is of good scientific evidence. 
 Patients, who are at risk for the conditions listed above or are on strict intake and 
output regulation, would benefit from receiving 5% human albumin as appropriate to the 
patient’s specific needs in an effort to reduce the adverse effects of an increased vascular 
permeability.  Upon further research studies that include patients at risk for post-
perfusion syndrome, pulmonary hypertension, or increased vascular permeability with the 
post-operative cardiac complicated background this conclusion may be manipulated. 
Current research data suggests that there are no negative effects to the administration of 
human albumin versus normal saline when the use is appropriately indicated. This is a 
grade A recommendation. The Levels of Evidence presented are I, II & III and includes 
three randomized control trials. The strength of this recommendation is of strong 
scientific evidence. The next chapter will express the potential impact of these 
recommendations and how they are perceived upon presentation. 
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Literature Reviewed 
 
 
 
Authors & 
Year 
published 
Title Design Specific Solutions 
Compared 
Level of 
Evidence 
Devliln & 
Barletta 
 
2005 
Albumin for 
fluid 
resuscitation: 
Implications 
of the saline 
versus 
albumin fluid 
evaluation.  
Systematic 
Review 
0.9 Normal Saline, 
Lactated Ringers, 
Hetastarch, albumin, blood 
products 
 
 
Level II 
Diehl-
Oplinger & 
Kaminiski 
 
2004 
Choosing the 
right fluid to 
counter. 
Case Series 0.9 Normal Saline, 0.45% 
Saline, Sodium Chloride 
(3&5%) D5W, Lactated 
Ringers, Dextrose 
Solutions 
(20%,40%,50%,60%,70%), 
Human Albumin 5% & 
25% 
Level IV 
Finfer, 
Bellomo, 
Boyce, 
French, 
Myburgh & 
Norton 
 
2004 
A comparison 
of albumin 
and saline for 
fluid 
resuscitation 
in the 
intensive care 
unit. 
Randomized  
Control 
Trial 
Normal Saline,  
4% Human Albumin 
Level I 
Kruer & 
Ensor 
 
2012 
Colloids in 
the intensive 
care unit.  
Systematic 
Review 
Normal saline 0.9%, 
Lactated Ringers, Gelatin 
4%, Hydroxyethyl starch 
6%, Albumin 5%, Dextran. 
Level II 
Table 1 
 Literature reviewed which support the use of Human Albumin in the adult post-
operative patient who is experiencing hypotension secondary to hypovolemia. 
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Verheij, 
Lingen, 
Beishuizen, 
Christiaans, 
Jong, 
Girbes, 
Wisselink, 
Rauwerda, 
Huybregts, 
& 
Groeneveld 
 
2006 
Cardiac 
response is 
greater for 
colloid than 
saline fluid 
loading after 
cardiac or 
vascular 
surgery.  
Single-
centre, single 
blinded, 
randomized 
clinical trial 
Saline 0.9%, Gelatin 4%, 
Hydroxyethyl starch 6%, 
Albumin 5% 
Level I 
Trof, Sukul, 
Twish, 
Girbes, & 
Groeneveld 
 
2010 
Greater 
cardiac 
response of 
colloid than 
saline fluid 
loading in 
septic and 
non-septic 
critically ill 
patients with 
clinical 
hypovolemia. 
Single-
centre, single 
blinded, 
randomized 
clinical trial 
Saline 0.9%, Gelatin 4%, 
Hydroxyethyl starch 6%, 
Albumin 5% 
Level I 
Talasaz, 
Jahangard-
Rafsanjani, 
Ziaie, & 
Fahimi 
 
2012 
Evaluation of 
the pattern of 
human 
albumin 
utilization at a 
university 
hospital. 
Retrospective 
Comparative 
Study 
Human Albumin Level III 
Roberts & 
Bratton 
 
1998 
Colloid 
volume 
expanders: 
Problems, 
pitfalls, and 
possibilities. 
Systematic 
Review 
Human Albumin 5% & 
25%, Dextran 40 & 70, 
Gelatin 4%, Hetastarch, 
Pentastrach 
Level II 
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Table 2 
Literature reviewed which support the use of Normal Saline in the adult post-
operative patient who is experiencing hypotension secondary to hypovolemia. 
Authors & 
Year 
published 
Title Design Specific 
Solutions 
Compared 
Level of 
Evidence 
Roberts, 
Blackhall, 
Alderson, 
Bunn, 
Schierhout 
 
2011 
Human albumin 
solution for 
resuscitation and 
volume 
expansion in 
critically ill 
patients. 
Meta-analysis 
Randomized 
controlled trials 
Human 
Albumin, 
Lactated 
Ringers, Normal 
Saline,  
hydroyethyl 
starch 
Level I 
Vincent, 
Navickis,  
Wilkes 
 
2004 
Morbidity in 
hospitalized 
patients 
receiving human 
albumin: a meta-
analysis of 
randomized, 
controlled trials. 
Meta-analysis 
randomized 
control trials 
Human 
Albumin, 0.9 
Normal Saline, 
Lactated Ringers 
Level I 
Perel 
&Roberts 
 
2012 
Colloids versus 
crystalloids for 
fluid 
resuscitation in 
critically ill 
children. 
Systematic 
Review 
Normal Saline, 
Gelatin 
Hydroxyethyl 
Starch, Human 
Albumin  
Level I 
Petillia & 
Ruokonen 
 
2005 
Albumin has no 
benefit over 
saline in the 
critically ill. 
Systematic 
Review 
Normal Saline, 
4% Human 
Albumin 
Level I 
Andrews 
 
2011 
Cochrane 
Nursing Care 
Field: Human 
albumin for 
intra-dialytic 
hypotension in 
haemodialysis 
patients 
Systematic 
Review 
Saline, Human 
albumin, 
Gelatin, Starches 
Level III 
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Chapter 5: Discussion 
Implementation of Recommendations 
 
 I presented the evidence-based recommendations from the literature review to the 
Cardio-Thoracic Care Unit (CTCU) at Kettering Medical Center on June 11, 2013. My 
audience included staff nurses and the Unit Educator.  The presentation was completed 
with a poster session. I provided handouts that included the “Literature Reviewed” 
outlined in tables 1 and 2, the evidenced based recommendations, Appendix A, Appendix 
B, and references. 
 The audience was concerned about articles that supported normal saline in the use 
for all patients. The concern was that the generalizability of the normal saline might not 
have been studied enough in depth for all patient types. Their concerns were eased by the 
recommendations, as they specifically mention that patients who are experiencing 
hypotension secondary to hypovolemia post-operatively, are on strict intake and output 
regulation, and are at risk for post-perfusion syndrome, pulmonary hypertension, or 
increased vascular permeability should receive 5% human albumin in place of normal 
saline. Cost was not important to the audience as they felt their personal experience with 
the effectiveness of 5% human albumin warrants the increased price. Overall, the 
intended audience was pleased with the evidence-based recommendation and 
recommendations that were presented. 
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 The next step to implement this recommendation in CTCU was to familiarize the 
staff and physicians with the recommendation and to encourage the recommendations be 
considered for every patient receiving fluid replacement therapy. I met with Dr. Pavlina 
on August 2, 2013. Dr. Pavlina showed genuine interest in the topic. He currently favors 
5% human albumin for fluid replacement in his patients whom need volume replacement 
secondary to hypervolemia. He took the project handout and is going to read further into 
this project. It will be my next step to follow up with his outlook of the recommendations 
and further implement them into common practice into the CTCU. 
Implications of Recommendations 
 
 The recommendation I presented to the CTCU would also be beneficial to nursing 
and medical staff in the Cardiac Intensive Care Unit, surgical and cardiac step-down 
units, and the Post-Anesthesia Care Unit at Kettering Medical Center and other regional 
area hospitals. These are units that provide care to post-surgery adult patients that 
experience hypotension secondary to hypovolemia. The implementation of the 
recommendations in additional units could result in decreased unnecessary spending, 
increased efficacy of the treatment, and increased safety of the patient population.  The 
extensive amount of research that was readily available indicates that this is an important 
practice consideration worldwide and should not be limited to one patient setting.  All 
applicable units, which provide fluid replacement therapy, would benefit from these 
recommendations.  
Further Research & Practice 
 
Choosing the correct therapy for each patient’s condition is an art form. We must 
be able to use our critical thinking skills to select the best possible therapy for our 
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ovolemia.
patients. Research reviews, research studies, and meta-analyses allow us to see a more 
diverse picture and choose the correct option for the dilemma at hand.  The reviews and 
articles that have been reviewed have similar content but conflicting conclusions. This is 
a result of limited patient populations and a need for further research.  
 The use of normal saline in post-operative, trauma, hypovolemic, ARDS, dialysis, 
and most other conditions is preferred over the use of 5% human albumin. Reviews that 
failed to include patients of cardiac or vascular nature are not able to defend the use of 
normal saline for these patients, as they can’t deflect the arguments of increased capillary 
permeability with an increase of fluid shift with appropriate hemodynamic stability data. 
Researchers must complete more studies that use a wide range of patient conditions, 
including cardiac compromised patients, to determine the efficacy of 5% human albumin 
compared to normal saline. This would increase the probability of having a more 
generalizable recommendation.  
 Cost was only a factor for measurement in very few studies and the significance 
of cost difference is only an added bonus for the use of normal saline. If there are added 
benefits for the of human albumin such as decreased fluid intake, decreased mortality, 
and increased cardiac output, then healthcare workers should not hesitate to use human 
albumin should.  Cost of the use of human albumin and the reimbursement value should 
be analyzed in future reviews.  
 In conclusion, the successfully presented recommendation is an evidenced-based 
practice. Health care providers must realize that it will be important for them to utilize 
evidence-based practice. Two recommendations were outlined in this project and they 
allowed for the contexts of the patient to determine the correct therapy. This individuality 
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of the generalized recommendations allows for the efficacious, safe, and cost-effective 
care patients deserve.  
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APPENDIX A 
 Therapeutic 
Studies: 
Investigating the 
results of treatment 
Prognostic 
Studies: 
Investigating the 
effect of a patient 
characteristic on 
the outcome of 
disease 
 
Diagnostic 
Studies: 
Investigating a 
diagnostic test 
 
Economic and 
Decision 
Analyses: 
Developing an 
economic or 
decision model 
 
Level I 
 
-  High quality 
randomized trial 
with statistically 
significant 
difference or no 
statistically 
significant 
difference but 
 narrow confidence 
intervals  
 -Systematic Review 
2 of Level I RCTs 
(and study results 
were 
homogenous3)  
 
 -High quality 
prospective 
study4 (all 
patients were 
enrolled at the 
same point in 
their disease with 
> 80% follow-up 
of enrolled 
patients)  
-Systematic review2 of 
Level I studies  
 
 - Testing of 
previously 
developed 
diagnostic criteria 
on consecutive 
patients (with 
universally 
applied reference 
“gold” standard)  
 -Systematic 
review2 of Level 
I studies  
 
  -  Sensible costs 
and alternatives; 
values obtained 
from many 
studies; with 
multiway 
sensitivity 
analyses  
 - Systematic 
review2 of 
Level I studies  
 
Level II 
 
-Lesser quality 
RCT (e.g. < 80% 
follow-up, no 
blinding, or 
improper 
randomization)  
-Retrospective6 
study- Untreated 
controls from an 
RCT 
- Lesser quality 
prospective study 
 -Development of 
diagnostic criteria 
on consecutive 
patients (with 
universally 
applied reference  
  -  Sensible costs 
and 
alternatives; 
values obtained 
from limited 
studies; with 
multiway 
Table 3 
Levels of Evidence for Primary Research Question 
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 -Prospective4 
comparative 
study5  
-Systematic 
review2 of Level 
II studies or Level 
I studies with 
inconsistent results  
 
(e.g., patients 
enrolled at different 
points in their 
disease or <80% 
follow-up). 
- Systematic 
review2 of Level II 
studies 
 
“gold” standard)  
- Systematic 
review2 of Level 
II studies  
 
sensitivity 
analyses  
 - Systematic 
review2 of 
Level II studies  
 
Level III 
 
 -  Case control 
study7  
 -Retrospective6 
comparative  
study5  
 -Systematic 
review2 of Level 
III studies  
- Case control 
study7 
 
 -  Study of non-
consecutive 
patients; without 
consistently 
applied reference 
“gold” standard  
-  Systematic review2 of 
Level III studies  
 
- Analyses based 
on limited 
alternatives and 
costs; and poor 
estimates 
- Systematic 
review2 of Level 
III studies 
 
Level IV 
 
-Case Series8 -Case Series 
 
- Case-control 
study 
- Poor reference 
standard 
- Analyses with no 
sensitivity 
analyses 
 
Level V 
 
-Expert Opinion 
 
-Expert Opinion 
 
-Expert Opinion 
 
-Expert Opinion 
 
1. A complete assessment of quality of individual studies requires critical appraisal of all aspects of the 
study design. 
2. A combination of results from two or more prior studies. 
3. Studies provided consistent results. 
4. Study was started before the first patient enrolled. 
5. Patients treated one way (e.g. cemented hip arthroplasty) com- pared with a group of patients treated 
in another way (e.g. unce- mented hip arthroplasty) at the same institution. 
6. The study was started after the first patient enrolled. 
7. Patients identified for the study based on their outcome, called "cases"; e.g. failed total arthroplasty, 
are compared to those who did not have outcome, called "controls"; e.g. successful total hip 
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arthroplasty. 
8. Patients treated one way with no comparison group of patients treated in another way. 
(Rahman & Pukui, 2002) 
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APPENDIX B 
 
Level of Evidence Grade Criteria 
A  (Strong Scientific Evidence) Statistically significant evidence of benefit from >2 
properly randomized trials (RCTs), OR evidence 
from one properly conducted RCT AND one 
properly conducted meta-analysis, OR evidence 
from multiple RCTs with a clear majority of the 
properly conducted trials showing statistically 
significant evidence of benefit AND with supporting 
evidence in basic science, animal studies, or theory. 
B  (Good Scientific Evidence) Statistically significant evidence of benefit from 1-2 
properly randomized trials, OR evidence of benefit 
from >1 properly conducted meta-analysis OR 
evidence of benefit from >1 cohort/case-
control/non-randomized trials AND with supporting 
evidence in basic science, animal studies, or theory. 
This grade applies to situations in which a well 
designed randomized controlled trial reports 
negative results but stands in contrast to the positive 
efficacy results of multiple other less well designed 
trials or a well designed meta-analysis, while 
awaiting confirmatory evidence from an additional 
well designed randomized controlled trial. 
C  (Unclear or Conflicting Scientific Evidence) Evidence of benefit from >1 small RCT(s) without 
adequate size, power, statistical significance, or 
quality of design by objective criteria,* OR 
conflicting evidence from multiple RCTs without a 
clear majority of the properly conducted trials 
showing evidence of benefit or ineffectiveness, OR 
evidence of benefit from >1 cohort/case-
control/non-randomized trials AND without 
supporting evidence in basic science, animal studies, 
Table 4 
Evidence-based validated grading rationale 
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or theory, OR evidence of efficacy only from basic 
science, animal studies, or theory. 
D  (Fair Negative Scientific Evidence) Statistically significant negative evidence (i.e., lack 
of evidence of benefit) from cohort/case-
control/non-randomized trials, AND evidence in 
basic science, animal studies, or theory suggesting a 
lack of benefit. This grade also applies to situations 
in which >1 well designed randomized controlled 
trial reports negative results, notwithstanding the 
existence of positive efficacy results reported from 
other less well designed trials or a meta-analysis. 
(Note: if there is >1 negative randomized controlled 
trials that are well designed and highly compelling, 
this will result in a grade of "F" notwithstanding 
positive results from other less well designed 
studies.) 
F  (Strong Negative Scientific Evidence) Statistically significant negative evidence (i.e., lack 
of evidence of benefit) from >1 properly 
randomized adequately powered trial(s) of high-
quality design by objective criteria.* 
Lack of Evidence† Unable to evaluate efficacy due to lack of adequate 
available human data. 
* Objective criteria are derived from validated instruments for evaluating study quality, including the 5-
point scale developed by Jadad et al., in which a score below 4 is considered to indicate lesser quality 
methodologically (Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay 
HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled 
Clinical Trials 1996; 17[1]:1-12). 
 
† Listed separately in monographs in the "Historical or Theoretical Uses which Lack Sufficient 
Evidence" section. 
 
         (Natural Standard, 2010) 
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